芪苈强心胶囊联合心悦胶囊治疗冠心病经皮冠状动脉介入术后慢性心力衰竭临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R541.4

基金项目:

首都十大危险疾病科技成果推广项目(Z121100005512004);中央本级重大增减支项目(2060302)


Clinical Study on Qili Qiangxin Capsules Combined with Xinyue Capsules for Chronic Heart Failure After Percutaneous Coronary Intervention for Coronary Heart Disease
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察芪苈强心胶囊联合心悦胶囊治疗冠心病经皮冠状动脉介入术(PCI) 后慢性心力衰竭的 临床疗效。方法:将80 例冠心病PCI 后慢性心力衰竭患者按随机数字表法分为对照组及治疗组各40 例。对照 组予常规西药治疗,治疗组在对照组基础上加芪苈强心胶囊与心悦胶囊治疗。比较2 组治疗前后中医证候积 分、6 min 步行实验(6MWT) 测试距离,血浆N 末端B 型利钠肽原(NT-proBNP) 及超声心动图参数,评估 2 组心功能疗效及不良反应发生情况。结果:治疗后,治疗组心功能疗效优于对照组(P<0.05)。治疗后, 2 组中医证候积分、NT-proBNP、左心室舒张末期内径(LVEDD) 及左心室收缩末期内径(LVESD) 均较治疗 前减少(P<0.05),左心室射血分数(LVEF)、6MWT 测试距离增加(P<0.05),且治疗组中医证候积分、 NT-proBNP、LVEDD 及LVESD 小于对照组(P<0.05),LVEF、6MWT 测试距离大于对照组(P<0.05)。2 组 不良反应发生率比较,差异无统计学意义(P>0.05)。结论:芪苈强心胶囊联合心悦胶囊治疗PCI 后慢性心力 衰竭疗效确切,可有效改善患者心功能,提高活动耐量,安全性较高。

    Abstract:

    Abstract:Objective:To observe the clinical effect of the therapy of Qili Qiangxin Capsules combined with Xinyue Capsules on patients with chronic heart failure after percutaneous coronary intervention (PCI) for coronary heart disease. Methods:A total of 80 patients with chronic heart failure after PCI for coronary heart disease were divided into the control group and the treatment group by random number table method,with 40 cases in each group. The control group was treated with conventional western medicine, and the treatment group was additionally treated with the therapy of Qili Qiangxin Capsules combined with Xinyue Capsules based on the treatment of the control group. The traditional Chinese medicine (TCM) syndrome scores,the distance of 6-minute walking test (6MWT),the N-terminal pro-B-type natriuretic peptide (NT- proBNP) levels and echocardiographic parameters were compared between the two groups before and after treatment. The effects of the heart function and the occurrence of adverse reactions were evaluated between the two groups. Results:After treatment,the curative effect on the heart function in the treatment group was better than that in the control group (P<0.05). After treatment, the TCM syndrome scores,the NT-proBNP levels,the left ventricular end-diastolic diameters (LVEDD) and the left ventricular end-systolic diameters (LVESD) were decreased in the two groups when compared with those before treatment (P<0.05); the left ventricular ejection fraction (LVEF) and the distance of 6MWT were increased (P<0.05),the TCM syndrome scores,NT-proBNP level,LVEDD and LVESD in the treatment group were less than those in the control group (P<0.05),and the LVEF and the distance of 6MWT were more than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: The therapy of Qili Qiangxin Capsules combined with Xinyue Capsules has a definite effect on the treatment of chronic heart failure after PCI for coronary heart disease,which can effectively improve the heart function,activity tolerance and safety.

    参考文献
    相似文献
    引证文献
引用本文

管斌斌,郭小舟,李立志.芪苈强心胶囊联合心悦胶囊治疗冠心病经皮冠状动脉介入术后慢性心力衰竭临床研究[J].新中医,2023,55(5):86-90

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2023-03-15
  • 出版日期:
文章二维码